Delpharm
Delpharm, a leading contract development and manufacturing organisation (CDMO), is headquartered in France and operates extensively across Europe and beyond. Founded in 1998, Delpharm has established itself as a key player in the pharmaceutical industry, specialising in the production of solid forms, liquids, and semi-solids. The company is renowned for its commitment to quality and innovation, offering tailored solutions that meet the diverse needs of its clients. Delpharm's state-of-the-art facilities and adherence to stringent regulatory standards have positioned it as a trusted partner for pharmaceutical companies worldwide. With a focus on sustainability and efficiency, Delpharm continues to achieve significant milestones, reinforcing its reputation as a reliable provider in the competitive landscape of pharmaceutical manufacturing.
DitchCarbon Score
How does Delpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Delpharm's score of 55 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Delpharm's reported carbon emissions
In 2024, Delpharm reported total carbon emissions of approximately 37,662,000 kg CO2e for Scope 1 and 16,127,000 kg CO2e for Scope 2. The company's Scope 3 emissions were significantly higher, totalling about 680,660,000 kg CO2e. This data reflects a comprehensive approach to emissions reporting, covering all relevant scopes. For 2023, Delpharm's emissions were slightly higher, with Scope 1 emissions at about 39,887,000 kg CO2e and Scope 2 emissions at approximately 16,182,000 kg CO2e. Scope 3 emissions for that year were around 695,597,000 kg CO2e, indicating a consistent pattern of high emissions in this category. Delpharm has set ambitious reduction targets, aiming for a 42% reduction in absolute emissions for both Scope 1 and Scope 2 by early 2025. These targets have been submitted to the Science Based Targets initiative (SBTi) and are aligned with the global efforts to limit warming to 1.5°C. The commitment to these targets reflects Delpharm's proactive stance in addressing climate change within the pharmaceutical sector. Overall, Delpharm's emissions data and reduction initiatives demonstrate a commitment to sustainability and climate responsibility, with a clear focus on reducing their carbon footprint in the coming years.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 39,887,000 | 00,000,000 |
| Scope 2 | 16,182,000 | 00,000,000 |
| Scope 3 | 695,597,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Delpharm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
